Imitrex

Sumatriptan, the active ingredient in Imitrex, is a selective serotonin (5‑HT1B/1D) receptor agonist presented as a 20 mg nasal spray for intranasal use. It treats acute migraine attacks with or without aura in adult patients. The intranasal spray delivers the medication directly to the nasal mucosa, allowing rapid absorption and onset of action. It is authorized for prescription use throughout the European Union.

GNH USA supplies Imitrex as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sumatriptan is a selective serotonin (5‑HT1B/1D) receptor agonist used for acute migraine management.

Migraine with aura: provides rapid relief of headache and associated symptoms. Migraine without aura: reduces pain intensity and duration of attacks. Acute migraine attacks: aborts migraine episodes when taken at onset.

Common Side Effects: - Taste disturbance - Nasal irritation - Dizziness - Nausea

Serious or Rare Side Effects: - Chest pain or tightness - Serotonin syndrome - Severe allergic reaction (anaphylaxis)

Imitrex should be used with caution in certain patient groups and conditions.

Contraindicated in patients with known coronary artery disease: avoid use due to vasoconstrictive risk. Avoid in uncontrolled hypertension: may exacerbate blood pressure. Use with caution in patients with a history of stroke or transient ischemic attack: monitor neurologic status. Do not combine with other 5‑HT1 agonists or ergot derivatives: increased risk of vasospasm. Pregnancy and lactation: safety not established, prescribe only if benefit outweighs risk. Store at ambient temperature below 25 °C: keep in the original pack, protect from moisture and direct sunlight.

Sumatriptan may interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Ergot alkaloids: additive vasoconstriction. - Other triptans: cumulative serotonergic effect.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: monitor for serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase sumatriptan levels. - Antihypertensive agents: may blunt blood pressure response.